Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1077-1083, 2002;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgenthaler, N. G.
Right arrow Articles by Reiners, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgenthaler, N. G.
Right arrow Articles by Reiners, C.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:1077-1083.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Evaluation of a New Immunoradiometric and a New Immunoluminometric Assay for Thyroglobulin

Nils G. Morgenthaler1a, Juergen Froehlich1, Johann Rendl2, Marita Willnich1, Christine Alonso1, Andreas Bergmann1 and Christoph Reiners2

1 B.R.A.H.M.S Biotechnology Centre Hennigsdorf/Berlin, D-16761 Hennigsdorf bei Berlin, Germany.

2 Klinik für Nuklearmedizin, Universität Würzburg, D-97080 Würzburg, Germany.

aAddress correspondence to this author at: Research Department, B.R.A.H.M.S AG, Neuendorfstrasse 25, D-16761 Hennigsdorf bei Berlin, Germany. Fax 49-03302-883-451; e-mail n.morgenthaler{at}brahms.de.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: After removal of differentiated thyroid carcinoma (DTC), serum thyroglobulin (Tg) can indicate persistent or recurrent disease. We describe two novel two-step assays designed to measure low Tg concentrations.

Methods: We evaluated prototypes of the new IRMA, DYNOtest® Tg-pluS, and the new immunoluminometric assay (ILMA), LUMItest® Tg-pluS. In the first step, a high-salt incubation buffer leads to dissociation of Tg-Tg antibody complexes in serum and is intended to reduce nonspecific interference and interference of potential Tg autoantibodies in the system. We studied recovery of human Tg (from thyroid glands) added to horse serum. We also studied 58 patients with DTC in whom Tg values under thyroid-stimulating hormone (TSH) suppression and TSH stimulation (without thyroxine) were available.

Results: The detection limits were 0.04 µg/L Tg for the IRMA and 0.02 µg/L for the ILMA. Intraassay imprecision (CV) was <10% over the range of the calibration curve in both assays. The day-to-day CV was <20% at 0.2 µg/L for the IRMA and at 0.06 µg/L for the ILMA. No high-dose hook effect was seen with up to 200 000 µg/L added Tg or in dilutions of 12 patient sera with Tg values of 307–38 880 µg/L. Mean recovery of 50 µg Tg/L was 96% in those patients. Among 77 samples with Tg antibody values of 65.2–8150 kilounits/L, recovery by the IRMA was disturbed in 7 cases (9%) and by the ILMA in 9 cases (12%). Tg increased as measured in both assays in 50 of 58 patients after thyroxine withdrawal.

Conclusions: The new assays have improved precision for Tg <1 µg/L, and even low measured Tg concentrations respond physiologically to thyroxine withdrawal. The assays are free of a high-dose hook effect up to a Tg concentration of at least 38 000 µg/L and may further reduce Tg antibody interference.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The major clinical application for thyroglobulin (Tg)1 determination is the postoperative follow-up of patients with differentiated thyroid carcinoma (DTC), where any increase in serum Tg indicates residual thyroid tissue or persistent and recurrent disease (1)(2)(3)(4). However, serum Tg measurements are one of the most difficult biochemical tests to maintain with high precision and reliability [see Spencer et al. (5) for a detailed review]. Several requirements are generally accepted for valid Tg determinations: high sensitivity, high interassay precision over a period of 6–12 months, no high-dose hook effect when measuring very high Tg concentrations (e.g., to monitor therapy), and the introduction of a common standardization system (6).

A particularly problematic issue is Tg detection in the serum of patients with Tg antibodies (Tg-Abs). Depending on the assay system, this can lead to either false-positive or -negative values (5). To detect interference in the Tg determination, a recovery test is usually performed using Tg, from thyroid glands, in concentrations of ~50 µg/L. Measurements with disturbed recovery are discarded and will not be used for clinical decisions. This practice is strongly debated. Whereas several groups find recovery studies mandatory (7)(8)(9)(10), others question the rational (11) on the basis of different Tg immunoreactivities between the Tg present in a patient’s serum and the exogenous Tg from thyroid glands (12). Assay interference might not be detected because of differences between serum Tg in cancer patients and the Tg used for recovery. However, a positive Tg result in serum with Tg-Abs is considered valuable clinical information by some researchers (4), but others are adamant about rejecting any Tg detection in the presence of antibodies, regardless of whether Tg is detectable (13).

In the present study, we present two novel assays for Tg detection, using a stringent incubation protocol in high salt to reduce nonspecific and autoantibody-related interference.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
We evaluated prototypes of the new IRMA, DYNOtest® Tg-pluS, and the new immunoluminometric assay (ILMA), LUMItest® Tg-pluS (B.R.A.H.M.S AG, Hennigsdorf, Germany) regarding technical features and preliminary clinical performance in 58 patients with DTC for whom Tg values under thyroid-stimulating hormone (TSH) suppression and TSH stimulation were available.

clinical information on patients
We studied 58 patients with DTC who were routinely scheduled for a posttherapy whole-body 131I scan at the Nuclear Medicine outpatient department of the University Clinic Wuerzburg. Serum samples were taken before and after thyroxine (T4) withdrawal. All patients had initially been treated by total thyroidectomy followed by radioablation. The interference of Tg-Abs was studied in 77 patients with autoimmune thyroid disease (Hashimoto thyroiditis and atropic thyroiditis). Dilution studies were performed on 12 sera from patients with metastatic thyroid cancer. Informed consent was obtained from all study participants.

assay principle
The DYNOtest Tg-pluS (IRMA) and LUMItest Tg-pluS (ILMA) are two-step assays for the quantitative detection of Tg in human serum. In the first step, 100 µL of serum is added to tubes coated with affinity-purified rabbit polyclonal anti-Tg; 200 µL of high-salt incubation buffer (50 mmol/L Tris, pH 6.8, 1.5 mol/L NaCl, 5.0 mL/L Triton X-100, 20 g/L bovine serum albumin) is then added to each tube. The tubes are incubated without shaking at room temperature overnight. The high NaCl concentration is used to dissociate complexes of Tg and anti-Tg antibodies in the patient serum and to reduce their interference in the assay. After the tubes are washed twice with washing buffer (B.R.A.H.M.S AG), they are incubated for 2 h at room temperature with shaking. For the IRMA, we used 200 µL of a 125I-labeled murine anti-Tg monoclonal antibody in buffer (50 mmol/L sodium phosphate, pH 6.8, 25 mmol/L NaCl, 2.0 mL/L Triton X-100, 10 g/L bovine serum albumin) as tracer. For the ILMA, we used 200 µL of acridinium ester-labeled murine anti-Tg monoclonal antibody in the same buffer. After the tubes were washed three to four times, bound radioactivity was counted in a gamma counter for 1 min (IRMA) or the relative light units for the ILMA were detected in a luminometer. The cpm or relative light units were proportional to the Tg concentration of the patient serum.

Tg-Abs were determined in a commercially available competitive RIA, DYNOtest® anti-Tgn (B.R.A.H.M.S AG). The cutoff for positivity is 60 kilounits/L.

calibrators and controls
Tg concentrations were calculated using a calibration curve derived from human thyroid gland Tg in horse serum. Calibrators were adjusted to the current Tg IRMA, DYNOtest TgS (B.R.A.H.M.S AG), to contain 0.15, 0.8, 4.0, 20, 100, and 250 µg/L Tg. Calibration with CRM 457 (6) was performed, and 1 µg/L CRM 457 was measured as 0.5 µg/L in the DYNOtest Tg-pluS or LUMItest Tg-pluS. Two controls containing a defined amount of human serum Tg were included in each analytical run.

recovery
Tg recovery was calculated using 50 µg/L Tg (final concentration) from human thyroid glands added to horse serum.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
A typical calibration curve for the IRMA is shown in Fig. 1 . The calibrator curve for the ILMA was similar (not shown). Both assays responded to serum Tg from 0.15 to 250 µg/L.



View larger version (12K):
[in this window]
[in a new window]
  		Figure 1. Representative calibration curve for the DYNOtest Tg-pluS IRMA.

Tg concentrations were calculated using a calibration curve derived from human thyroid gland Tg in horse serum. Calibrators were calibrated against the current Tg IRMA, DYNOtest TgS, to contain 0.15, 0.8, 4.0, 20, 100, and 250 µg/L Tg.

INTRAASSAY, INTERASSAY, AND INTERLABORATORY CVS
The lower detection limit was 0.04 µg/L Tg for the IRMA and 0.02 µg/L for the ILMA. The intraassay CV (10 determinations per sample) was <10% over the range of the calibration curve for the IRMA (Fig. 2A ) and <5% for the ILMA (Fig. 2B ), respectively. The interassay CV was <=20% (10 determinations per sample) for the IRMA at 0.1 µg/L Tg with fresh tracer (not shown) and at 0.2 µg/L Tg with tracer at the expiration date (Fig. 2C ). The interassay CV for the ILMA was <10% over the range of the calibration curve and <20% at 0.06 µg/L (Fig. 2D ). The CV between different reagent lots (interlot CV, 10 determinations per sample) was determined by five operators using two counters and three reagent lots over a period of 12 months. All samples had a CV <12% (Fig. 2E ) or <15% (Fig. 2F ), respectively.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 2. Imprecision of the IRMA (A, C, and E) and ILMA (B, D, and F).

(A and B), intraassay CV (n = 10 runs); (C and D), interassay CV (n = 10 analytical runs); (E and F), CV between different reagent lots and operators (interlot CV; n = 10 analytical runs).

cross-reactivity and reliability
There was no cross-reactivity to horse Tg up to a concentration of 100 000 µg/L in either assay.

Assay linearity was confirmed using dilutions (1 part serum + 1 part diluent to 1 part serum + 31 parts diluent) of 10 different sera. All sera showed linear dilution in both assays, and the calculation of the original concentration in all dilutions was in agreement with the undiluted value. No pool effect was observed in the same 10 sera; the Tg determination in pooled sera produced the expected Tg concentrations.

no high-dose hook effect
To exclude a high-dose hook effect, Tg calibration material was diluted in human serum (highest concentration, 200 000 µg/L). As shown in Fig. 3A , even at the highest values the calibration curve of the IRMA remained in the plateau and did not decrease to lower or even negative values. Additionally, a total of 12 patient serum samples with Tg values of 307–38 880 µg/L were diluted and measured in the assay. All sera showed linear dilution in the IRMA without a high-dose hook effect (Fig. 3B ). Data for undiluted samples and 1:10 dilutions (1 part serum + 9 parts diluent) for some sera were extrapolated from the calibration curve (>250 µg/L). The precise Tg concentrations of these sera were calculated with the 1:100 (1 part serum + 99 parts diluent) and 1:1000 (1 part serum + 999 parts diluent) dilutions. Data for the ILMA were similar (not shown).



View larger version (26K):
[in this window]
[in a new window]
  		Figure 3. Lack of high-dose hook effect in the IRMA.

(A), Tg calibration material diluted in patient serum samples (highest concentration, 200 000 µg/L). (B), serial dilution of 12 patient sera with TG values of 307–38 880 µg/L. Dilutions: 1:1, undiluted sample; 1:10, 1 part serum + 9 parts diluent; 1:100, 1 part serum + 99 parts diluent; 1:1000, 1 part serum + 999 parts diluent; 1:10000, 1 part serum + 9999 parts diluent.

robustness and interferences
Both assays were robust with respect to changes in incubation temperature (17–29 °C) and incubation time (18 ± 4 h for the first incubation step, 2 h ± 30 min for the second incubation step). To test whether the assays were influenced by hemolysis, serum lipids, or bilirubin, we diluted three sera in normal plasma, plasma containing lysed blood cells, plasma containing serum lipids, or plasma containing bilirubin. Both assays were unaffected by hemoglobin up to 60 g/L, serum lipids up to 3.2 g/L, or bilirubin up to 200 g/L.

COMPARISON WITH ESTABLISHED Tg ASSAY
Both new assays were compared with the DYNOtest Tg-S, using serum samples over the entire range of the calibration curve. Results of the regression analysis are shown in Fig. 4 .




View larger version (26K):
[in this window]
[in a new window]
  		Figure 4. Linear regression analyses of the established DYNOtest Tg-S and the new DYNOtest Tg-pluS assays (A), the established DYNOtest Tg-S and the new LUMItest Tg-pluS assays (B), and the LUMItest Tg-pluS and the DYNOtest Tg-pluS assays (C).

(A), results for regression analysis using Tg concentrations from 194 serum samples: R2 = 0.97; Sy|x = 9.59; slope, 0.94 [95% confidence interval (CI), 0.92–0.97]; intercept, -1.18 (95% CI, -2.7 to 0.37). (B), result for linear regression analysis using Tg concentrations from 76 serum samples: R2 = 0.99; Sy|x = 4.42; slope, 0.82 (95% CI, 0.80–0.83); intercept, 0.03 (95% CI, -1.14 to 1.20). (C), results for linear regression analysis using Tg concentrations from 161 serum samples: R2 = 0.99; Sy|x = 1.74; slope, 0.99 (95% CI, 0.98–0.99); intercept, 0.09 (95% CI, -0.24 to 0.42).

INTERFERENCE FROM Tg-Abs
Interference from Tg-Abs was tested in 77 sera that had tested positive for Tg-Abs (minimum, 65.2 kilounits/L; maximum, 8150 kilounits/L; median, 181 kilounits/L). Recovery (50 µg/L) was disturbed in the ILMA in nine sera (12%), and in the IRMA in seven sera (9%), respectively. Of those sera, six were disturbed in both assays, one serum only in the IRMA, and three only in the ILMA (these three sera had a recovery of 69%). Recovery was considered undisturbed if measured Tg values were 70–130% of the added Tg. Except for one serum in the IRMA, all sera with disturbed recoveries had Tg values <1 µg/L (Fig. 5 ) and autoantibodies >800 kilounits/L (not shown).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 5. Interference with Tg-Abs in 77 sera from patients with autoimmune thyroid disease.

Relationship between Tg concentration and Tg recovery for the IRMA (A) and the ILMA (B). Recovery was considered undisturbed if measured Tg values were 70–130% of added Tg (indicated by the dotted lines). Data points below the FAS were set to 0.01.

Among the 116 samples from patients receiving or not receiving T4, the mean recovery in the IRMA was 96% (median, 97%).

Tg DETERMINATION BEFORE AND AFTER T4 WITHDRAWAL
Evaluation of 58 paired thyroid cancer samples (with and without L-T4) demonstrated an increase in Tg (greater than CV at the respective concentration) in 50 cases and constant values in 8 cases (Fig. 6 ). Samples with Tg values below the functional assay sensitivity (FAS) should be considered undetectable.



View larger version (43K):
[in this window]
[in a new window]
  		Figure 6. Tg values for patients receiving or not receiving T4 suppression therapy.

Data below the FAS should be considered undetectable.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The determination of Tg in serum is an important diagnostic tool in the follow-up of patients with DTC. Assay requirements include a low detection limit and low imprecision at low Tg concentrations (14). The new assays described here demonstrate the lowest detection limits reported to date. Furthermore, the interassay CV (also taking into account different laboratories) was <10% in the clinically important range of 0.5–1 µg/L. T4 withdrawal increased the detectable Tg in most thyroid cancer patients for whom low Tg values were measured, indicating that this low Tg was indeed secreted by residual thyroid tissue and that the result was not an assay artifact. The long-term precision for Tg <1 µg/L allows prolonged clinical evaluation of patients with such low Tg concentrations. Although some physicians do not draw clinical conclusions from Tg values <1–2 µg/L (15), the assay precision is excellent throughout the clinically relevant measuring range, potentially allowing improved monitoring.

Some physicians would prefer "less sensitive" assays because it is sometimes difficult to verify the source of very low Tg concentrations (<0.5 µg/L) by additional imaging diagnostics, and confusion for the physician and the patient may occur (15). Others, however, argue in favor of a complete evaluation of patients with detectable serum Tg, irrespective of the concentration (4). It is possible that very low Tg concentrations do not require immediate treatment. The changes in serum Tg over a certain period or after T4 withdrawal are more informative than a single Tg determination (14). This is of special clinical relevance when recombinant TSH is used for exogenous stimulation of thyroid tissue, which is not as intense as stimulation after T4 withdrawal. Highly sensitive Tg assays that can distinguish a Tg increase from 0.2 to 0.8 µg/L in one patient and confirm a constant low Tg of 0.8 µg/L in another patient may be clinically valuable because only the first patient might need to undergo additional diagnoses or treatment. As increasingly sensitive assays become available and ultrasensitive methods such as PCR of Tg mRNA are considered (16)(17), the Tg threshold or Tg increase at which clinical intervention should occur must be reevaluated in clinical studies.

Many IRMAs and ILMAs have the limitation of a high-dose hook effect (5), which is the result of "neutralization" of the tracer antibody by excess Tg, so that no sandwich complex is generated on the solid phase. An important improvement of the assays described here was the lack of such a high-dose hook effect in all samples with very high Tg concentrations.

Other Tg assays have tried to overcome the limitation of Tg determination in the presence of Tg-Abs, for example, by use of capture antibodies specific for certain Tg epitopes (18). However, in clinical evaluations, interference by Tg-Abs was still reported (19). In the two assays studied here, the frequencies of disturbed recovery in Tg-Ab-positive samples were considerably lower (12% for the ILMA, 9% for the IRMA) than have been reported in other systems [50–68% (19)].

The use of recovery to assess any interference in the Tg assay is supported by several groups (7)(8)(9)(10) who have found that the detection of Tg-Abs may not be sufficient for this purpose. Others favor Tg-Ab detection and consider recovery data in the presence of Tg-Abs invalid (4)(11). Furthermore, the ratio between recovery Tg and sample Tg is an important factor. The use of 50 µg/L Tg in recovery studies might not allow the detection of slight interferences by autoantibodies because the autoantibody concentration does not allow any conclusions on immunoreactivity with serum Tg. Thus, serum Tg values <5 µg/L might not be detected, even if the recovery of 50 µg/L is undisturbed (>70%). As a consequence, relapse or spreading of thyroid cancer could occur.

The conditions of the two-step assays (overnight incubation and 1.5 mol/L NaCl) increased the binding of Tg to the polyclonal capture antibodies, whereas nonspecific interference that might influence the assays was reduced. Furthermore, under these stringent conditions, complexes of Tg with anti-Tg antibodies are disrupted. As suggested by Mariotti et al. (19), however, the problem of Tg detection in the presence of Tg-Abs may not be limited to assay problems. It may also reflect a faster clearance of the antigen-antibody complex from the patient in vivo, in which case the negative result in vitro may be analytically correct but is unable to exclude residual Tg-producing DTC tissue in the patient. Another point of criticism is the difference between serum Tg in patients and the Tg from thyroid glands used for recovery studies (12). Finally, the difference between serum Tg isoforms in healthy individuals and patients with thyroid cancer may also be relevant (20). We are currently evaluating whether a low-dose recovery consisting of 1 µg/L serum Tg is able to alleviate some of these problems because it excludes structural and immunologic differences between serum Tg and colloidal Tg. Ongoing studies in a European multicenter trial will clarify whether this approach has a clinical benefit over the conventional recovery regime.

The excellent correlation of the new TG plus assay to the established and broadly used DYNOtest TG-S justifies the use of earlier Tg determinations in the same patient and makes additional measurements with stored serum samples less important. Despite the introduction of CRM 457 (6), a comparison of Tg values measured with different Tg assays is still difficult because no assay is calibrated 1:1 to the CRM (21). Calibration of the DYNOtest Tg-pluS with the CRM 457 produced 50.1% activity. Thus, 1 ng of CRM 457 is equivalent to 0.5 ng in this assay.

In conclusion, we established IRMA and ILMA assays for Tg determination with low detection limits and excellent precision at Tg concentrations as low as 0.2 (or 0.06) µg/L. Both assays are free of hook effects to the very high concentrations tested and appear to be less influenced by Tg-Abs. The clinical benefits of these new assays are currently under investigation in a European multi center trial.


   Acknowledgments
 
We thank I. Grelle (Klinik für Nuklearmedizin, Universität Würzburg) and C. Walter, M. Ullrich, M. Talke, C. Fischer-Schulz, and D. Hintzen (B.R.A.H.M.S AG, Research and Development) for excellent technical assistance.


   Footnotes
 
1 Nonstandard abbreviations: Tg, thyroglobulin; TG-Ab, anti-thyroglobulin antibody; DTC, differentiated thyroid carcinoma; ILMA, immunoluminometric assay; TSH, thyroid-stimulating hormone; T4, thyroxine; FAS, functional assay sensitivity; and CI, confidence interval.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Van Herle AJ, Uller RP, Matthews NI, Brown J. Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 1973;52:1320-1327.
  2. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998;138:249-252.[ISI][Medline] [Order article via Infotrieve]
  3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.[Free Full Text]
  4. Pacini F, Pinchera A. Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Biochimie 1999;81:463-467.[Medline] [Order article via Infotrieve]
  5. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996;42:164-173.[Abstract/Free Full Text]
  6. Feldt-Rasmussen U, Profilis C, Colinet E, Schlumberger M, Balck E. Purification and assessment of stability and homogeneity of human thyroglobulin reference material. Exp Clin Endocrinol 1994;102:87-91.
  7. Sapin R, Gasser F, Chambron J. Recovery determination in 600 sera analyzed for thyroglobulin with a recently commercialized IRMA kit. Clin Chem 1992;38:1920-1921.[Free Full Text]
  8. Ligabue A, Poggioli MC, Zacchini A. Interference of specific autoantibodies in the assessment of serum thyroglobulin. J Nucl Biol Med 1993;37:273-279.
  9. Schaadt B, Feldt-Rasmussen U, Rasmusson B, Torring H, Foder B, Jorgensen K, et al. Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma. Thyroid 1995;5:165-170.[ISI][Medline] [Order article via Infotrieve]
  10. Bourrel F, Hoff M, Regis H, Courriere P, Caron P. Immunoradiometric assay of thyroglobulin in patients with differentiated thyroid carcinomas: need for thyroglobulin recovery tests. Clin Chem Lab Med 1998;36:725-730.[ISI][Medline] [Order article via Infotrieve]
  11. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin Chem 1996;42:661-663.[Free Full Text]
  12. Schulz R, Bethauser H, Stempka L, Heilig B, Moll A, Hufner M. Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men. Eur J Clin Invest 1989;19:459-463.[ISI][Medline] [Order article via Infotrieve]
  13. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-1127.[Abstract/Free Full Text]
  14. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435-441.[ISI][Medline] [Order article via Infotrieve]
  15. Mikosch P, Gallowitsch HJ, Kresnik E, Unterweger O, Gomez I, Lind P. Comparison of two thyroglobulin immunoradiometric assays on the basis of comprehensive imaging in differentiated thyroid carcinoma. Thyroid 1999;9:933-941.[ISI][Medline] [Order article via Infotrieve]
  16. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:4435-4442.[Abstract/Free Full Text]
  17. Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH, et al. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4037-4042.[Abstract/Free Full Text]
  18. Marquet PY, Daver A, Sapin R, Bridgi B, Muratet JP, Hartmann DJ, et al. Highly sensitive immunoradiometric assay for serum thyroglobulin with minimal interference from autoantibodies. Clin Chem 1996;42:258-262.[Abstract/Free Full Text]
  19. Mariotti S, Barbesino G, Caturegli P, Marino M, Manetti L, Pacini F, et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal?. J Clin Endocrinol Metab 1995;80:468-472.[Abstract]
  20. Kohno Y, Tarutani O, Sakata S, Nakajima H. Monoclonal antibodies to thyroglobulin elucidate differences in protein structure of thyroglobulin in healthy individuals and those with papillary adenocarcinoma. J Clin Endocrinol Metab 1985;61:343-350.[Abstract]
  21. Sapin R, Schlienger JL. Ambiguités des dosages de thyroglobuline. Ann Biol Clin 1998;56:41-47.



The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al.
Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. C. Hovens, M. P. Stokkel, J. Kievit, E. P. Corssmit, A. M. Pereira, J. A. Romijn, and J. W. A. Smit
Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2610 - 2615.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti
Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
R Gorges, M Maniecki, W Jentzen, S. n-Y. Sheu, K Mann, A Bockisch, and O E Janssen
Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy
Eur. J. Endocrinol., July 1, 2005; 153(1): 49 - 55.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. M. Preissner, D. J. O'Kane, R. J. Singh, J. C. Morris, and S. K. G. Grebe
Phantoms in the Assay Tube: Heterophile Antibody Interferences in Serum Thyroglobulin Assays
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3069 - 3074.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgenthaler, N. G.
Right arrow Articles by Reiners, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgenthaler, N. G.
Right arrow Articles by Reiners, C.
Related Collections
Right arrow Endocrinology and Metabolism

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS